Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

South of the Border: Sanofi’s Tailored Approach To Emerging Markets

This article was originally published in The Pink Sheet Daily

Executive Summary

Sanofi’s recent acquisition of Medley, Brazil’s leading generics manufacturer, reflects its strategy of going local — and generic — in emerging markets.

You may also be interested in...



Sanofi CSO David-Alexandre Gros On The Next Wave Of Growth In Emerging Markets: An Interview With PharmAsia News

During a visit to Shanghai, Sanofi’s chief strategy officer sits down to talk about the company’s playbook for emerging markets, which focuses on both the BRIC countries and up-and-coming markets like Vietnam, Colombia and Nigeria.

Watson Takes Stake In Brazil's Moksha8

The Sao Paolo-based company will market about a dozen of Watson's generics in Mexico and Brazil, with potential for more.

Watson Takes Stake In Brazil's Moksha8

The Sao Paolo-based company will market about a dozen of Watson's generics in Mexico and Brazil, with potential for more.

Related Content

Topics

UsernamePublicRestriction

Register

ID014775

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel